David Lucchino's career is firmly rooted in the world's most important life sciences cluster - Kendall Square in Cambridge, MA. David is the President and CEO of Frequency Therapeutics (Nasdaq:FREQ), which he co-founded with MIT Institute Professor Robert S. Langer, ScD, and Jeffrey Karp, PhD, Professor at Brigham and Women’s Hospital, Harvard Medical School. David is Chairman of MassBio, the state's trade association of 1,300 life sciences firms. He is a trustee of Mt. Auburn Hospital, a Harvard Medical School facility; a board member at NOLS and the Multiple Myeloma Research Foundation.

David sold his first MIT start up Semprus BioSciences to Teleflex for a upfront and earn out transaction totaling $80M. Under his stewardship, Semprus won MIT's famed $100K Entrepreneurial Competition and then went on to secure $28.5M in financing, $8M in DoD funding, and achieved FDA and CE Mark approvals for Semprus' first product. David's leadership role also extended to Capital Hill where as an AdvaMed board member he advocated for greater biomedical entrepreneurial support to members of the US Senate and House of Representatives.